Daré Bioscience, Inc. (DARE)
| Market Cap | 11.32M -58.8% |
| Revenue (ttm) | 1.37M +10,429.4% |
| Net Income | -10.99M |
| EPS | -0.78 |
| Shares Out | 15.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 469,510 |
| Open | 0.8023 |
| Previous Close | 0.8074 |
| Day's Range | 0.7117 - 0.8456 |
| 52-Week Range | 0.6900 - 3.7800 |
| Beta | 1.01 |
| Analysts | Strong Buy |
| Price Target | 8.33 (+1,024.92%) |
| Est. Earnings | Nov 12, 2026 |
About DARE
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor sympto... [Read more]
Financial Performance
In 2025, Daré Bioscience's revenue was $1.03 million, an increase of 10429.36% compared to the previous year's $9,784. Losses were -$13.40 million, 230.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for DARE stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 1,024.92% from the latest price.
News
Daré Bioscience Proxy statement: Proxy filing
Daré Bioscience filed a proxy statement on September 23, 2026, providing details for shareholder voting and corporate governance matters.
Dare Bioscience publishes results from Sildenafil Cream study
Dare Bioscience (DARE) announced the publication of results from a Phase 1 clinical study evaluating the safety and systemic pharmacokinetics of topical Sildenafil Cream, 3.6% in healthy adult men in…
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Published Phase 1 data in Sexual Medicine strengthen the scientific foundation for Daré Bioscience's proprietary topical Sildenafil Cream, 3.6%
Daré Bioscience Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two revenue-generating products are launching in 2026, supported by a scalable digital health platform and strong provider relationships. Late-stage clinical programs for contraception and HPV are set for key data readouts next year, with a robust pipeline fueled by non-dilutive funding.
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
View the video webcast here
Daré Bioscience Slides: Corporate presentation
Daré Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Dare Bioscience announces new $908,000 NIH funding award to advance DARE-PTB2
Dare Bioscience (DARE) announced that it received a new notice of award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, or NICHD, of the National…
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of approximately $1.3 million
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Video webcast now available here
Daré Bioscience Transcript: Investor update
A pivotal period is underway with new product launches, including Flora Sync LF5 and DARE to PLAY, and major clinical milestones expected next year for Ovaprene and DARE-HPV. The strategy leverages grant funding, digital engagement, and provider relationships for capital-efficient growth.
Daré Bioscience's Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré's proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposure Company continues activities necess...
Daré Bioscience Registration statement: Registration filing
Daré Bioscience filed a registration statement on August 26, 2026, providing details about a securities offering with the SEC.
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
President & CEO, Sabrina Martucci Johnson, discusses the Company's shift to commercial stage, upcoming revenue opportunities, Ovaprene's positive interim Phase 3 results and what could drive value ove...
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
National recognition comes as Daré Bioscience advances a multi-product women's health strategy across commercialization, clinical development and first-in-category innovation National recognition come...
Dare Bioscience announces pricing of $6M registered direct offering
Dare Bioscience (DARE) announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the company’s common ...
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Earnings Call Transcript: Q2 2026
Transitioning to a commercial-stage company, the business launched its first product and is preparing a second for prescription dispensing, with a third targeted for 2027. Financials show improved net loss and increased revenue, supported by non-dilutive funding and a scalable commercial platform.
Daré Bioscience Quarterly report: Q2 2026
Daré Bioscience has published its Q2 2026 quarterly earnings report on August 13, 2026.
Daré Bioscience Earnings release: Q2 2026
Daré Bioscience released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women's Health Strategy Advances
Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July
Daré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
A featured menopause telehealth option is now available to women exploring DARE to PLAY™, advancing Daré's strategy to build a trusted women's health ecosystem spanning products, education and access ...
Daré Bioscience Slides: Corporate presentation
Daré Bioscience has posted slides in relation to its latest quarterly earnings report, which was published on July 24, 2026.
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science...
Daré Bioscience Transcript: Virtual Investor Closing Bell
The event detailed a transition from development to commercialization, with two products—Flora Sync LF5 and DARE to PLAY—launching in 2024, supported by a robust pipeline and over $75 million in non-dilutive funding. Key clinical milestones for Ovaprene and DARE-HPV are expected in the next year, while the business model leverages digital platforms and provider networks for rapid adoption.